JP2013516469A - 高齢者に保護免疫を提供するための方法及び組成物 - Google Patents
高齢者に保護免疫を提供するための方法及び組成物 Download PDFInfo
- Publication number
- JP2013516469A JP2013516469A JP2012548078A JP2012548078A JP2013516469A JP 2013516469 A JP2013516469 A JP 2013516469A JP 2012548078 A JP2012548078 A JP 2012548078A JP 2012548078 A JP2012548078 A JP 2012548078A JP 2013516469 A JP2013516469 A JP 2013516469A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- elderly
- composition
- flagellin
- human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 97
- 238000000034 method Methods 0.000 title claims abstract description 66
- 230000001681 protective effect Effects 0.000 title claims abstract description 10
- 230000036039 immunity Effects 0.000 title claims description 10
- 102000036639 antigens Human genes 0.000 claims abstract description 131
- 108091007433 antigens Proteins 0.000 claims abstract description 131
- 239000000427 antigen Substances 0.000 claims abstract description 130
- 108010040721 Flagellin Proteins 0.000 claims abstract description 74
- 230000028993 immune response Effects 0.000 claims abstract description 45
- 206010022000 influenza Diseases 0.000 claims description 42
- 102000037865 fusion proteins Human genes 0.000 claims description 39
- 108020001507 fusion proteins Proteins 0.000 claims description 39
- 101710154606 Hemagglutinin Proteins 0.000 claims description 38
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 38
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 38
- 101710176177 Protein A56 Proteins 0.000 claims description 38
- 239000000185 hemagglutinin Substances 0.000 claims description 37
- 238000002255 vaccination Methods 0.000 claims description 22
- 239000002245 particle Substances 0.000 claims description 19
- 230000005875 antibody response Effects 0.000 claims description 17
- 230000004936 stimulating effect Effects 0.000 claims description 13
- 230000014759 maintenance of location Effects 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 239000002105 nanoparticle Substances 0.000 claims description 6
- 230000003472 neutralizing effect Effects 0.000 claims description 6
- 241000282412 Homo Species 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 239000000277 virosome Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000004005 microsphere Substances 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 30
- 229960005486 vaccine Drugs 0.000 description 28
- 239000013612 plasmid Substances 0.000 description 25
- 108020004414 DNA Proteins 0.000 description 14
- 230000004044 response Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 238000005119 centrifugation Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 229960003971 influenza vaccine Drugs 0.000 description 9
- 108010074051 C-Reactive Protein Proteins 0.000 description 8
- 102100032752 C-reactive protein Human genes 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 238000010828 elution Methods 0.000 description 8
- 208000037797 influenza A Diseases 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- JANQQPWTLXUSCD-UHFFFAOYSA-N 9-(5,5-difluoro-5-phosphonopentyl)guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2CCCCC(F)(F)P(O)(O)=O JANQQPWTLXUSCD-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000005571 anion exchange chromatography Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000012537 formulation buffer Substances 0.000 description 6
- 230000005847 immunogenicity Effects 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 239000004202 carbamide Substances 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- -1 for example Substances 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 229940124894 Fluzone Drugs 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 4
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 4
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 4
- 239000008351 acetate buffer Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 4
- 229940125575 vaccine candidate Drugs 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 239000012512 bulk drug substance Substances 0.000 description 3
- 239000013592 cell lysate Substances 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940126534 drug product Drugs 0.000 description 3
- 239000012526 feed medium Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000000265 homogenisation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000013411 master cell bank Methods 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 241000228212 Aspergillus Species 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010069767 H1N1 influenza Diseases 0.000 description 2
- 241000228404 Histoplasma capsulatum Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 102000005348 Neuraminidase Human genes 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000233872 Pneumocystis carinii Species 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000012501 chromatography medium Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 210000000852 deltoid muscle Anatomy 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000006384 oligomerization reaction Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 201000010740 swine influenza Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 description 1
- 206010055048 Allergy to vaccine Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000223203 Coccidioides Species 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101900159346 Influenza A virus Hemagglutinin Proteins 0.000 description 1
- 241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 241001505293 Plasmodium ovale Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- 201000009976 Plasmodium vivax malaria Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 101150040096 SFT2 gene Proteins 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 201000005010 Streptococcus pneumonia Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004929 Triton X-114 Polymers 0.000 description 1
- 208000005469 Vivax Malaria Diseases 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000013377 clone selection method Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 101150104647 fljB gene Proteins 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 229940047650 haemophilus influenzae Drugs 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 108010003052 omptin outer membrane protease Proteins 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 229940118768 plasmodium malariae Drugs 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000000601 reactogenic effect Effects 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000172 trivalent influenza vaccine Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29259310P | 2010-01-06 | 2010-01-06 | |
| US61/292,593 | 2010-01-06 | ||
| PCT/US2011/020159 WO2011084967A2 (en) | 2010-01-06 | 2011-01-05 | Methods and compositions for providing protective immunity in the elderly |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013516469A true JP2013516469A (ja) | 2013-05-13 |
| JP2013516469A5 JP2013516469A5 (enExample) | 2014-02-20 |
Family
ID=44306116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012548078A Pending JP2013516469A (ja) | 2010-01-06 | 2011-01-05 | 高齢者に保護免疫を提供するための方法及び組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20130095130A1 (enExample) |
| EP (1) | EP2521563B1 (enExample) |
| JP (1) | JP2013516469A (enExample) |
| KR (1) | KR20120129893A (enExample) |
| CN (1) | CN102740872A (enExample) |
| AU (1) | AU2011203740B2 (enExample) |
| CA (1) | CA2786306A1 (enExample) |
| MX (1) | MX2012007916A (enExample) |
| SG (1) | SG182305A1 (enExample) |
| WO (1) | WO2011084967A2 (enExample) |
| ZA (1) | ZA201205273B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008527009A (ja) | 2005-01-19 | 2008-07-24 | バクシネート コーポレーション | 病原体関連分子パターンおよび抗原を含む組成物ならびに免疫応答を刺激するためのそれらの使用 |
| EP2476432B1 (en) | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| SG190562A1 (en) | 2008-04-18 | 2013-06-28 | Vaxinnate Corp | Deletion mutants of flagellin and methods of use |
| US8932598B2 (en) * | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007530430A (ja) * | 2003-07-14 | 2007-11-01 | コロラド ステイト ユニバーシティ リサーチ ファウンデイション | パターン認識受容体−リガンド：脂質複合体を使用するワクチン |
| JP2008523819A (ja) * | 2004-12-16 | 2008-07-10 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | Ｙｅｒｓｉｎｉａｐｅｓｔｉｓの免疫療法におけるフラジェリンの使用 |
| JP2008524261A (ja) * | 2004-12-21 | 2008-07-10 | バクシネート コーポレーション | インフルエンザウイルスタンパク質の組成物およびその使用方法 |
| WO2009128950A2 (en) * | 2008-04-18 | 2009-10-22 | Vaxinnate Corporation | Deletion mutants of flagellin and methods of use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5976552A (en) * | 1995-04-28 | 1999-11-02 | Protein Sciences Corporation | Virus vaccines |
| US20030232055A1 (en) * | 2000-07-31 | 2003-12-18 | Ruslan Medzhitov | Innate immune system-directed vaccines |
| US20090162400A1 (en) * | 2004-12-21 | 2009-06-25 | Powell Thomas J | Compositions of influenza viral proteins and methods of use thereof |
| CA2596079A1 (en) * | 2005-01-31 | 2006-08-10 | Vaxinnate Corporation | Novel polypeptide ligands for toll-like receptor 2 (tlr2) |
| EP1863529A1 (en) * | 2005-03-23 | 2007-12-12 | GlaxoSmithKline Biologicals S.A. | Novel composition |
| EP2476432B1 (en) * | 2006-03-07 | 2015-08-19 | Vaxinnate Corporation | Compositions that include hemagglutinin, methods of making and methods of use thereof |
| WO2009130618A2 (en) * | 2008-04-25 | 2009-10-29 | Institute For Systems Biology | Flagellin polypeptide vaccines |
-
2011
- 2011-01-05 MX MX2012007916A patent/MX2012007916A/es not_active Application Discontinuation
- 2011-01-05 WO PCT/US2011/020159 patent/WO2011084967A2/en not_active Ceased
- 2011-01-05 JP JP2012548078A patent/JP2013516469A/ja active Pending
- 2011-01-05 CN CN2011800069618A patent/CN102740872A/zh active Pending
- 2011-01-05 KR KR1020127019714A patent/KR20120129893A/ko not_active Ceased
- 2011-01-05 EP EP11732058.0A patent/EP2521563B1/en not_active Not-in-force
- 2011-01-05 AU AU2011203740A patent/AU2011203740B2/en not_active Ceased
- 2011-01-05 US US13/519,912 patent/US20130095130A1/en not_active Abandoned
- 2011-01-05 SG SG2012048617A patent/SG182305A1/en unknown
- 2011-01-05 CA CA2786306A patent/CA2786306A1/en not_active Abandoned
-
2012
- 2012-07-16 ZA ZA2012/05273A patent/ZA201205273B/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007530430A (ja) * | 2003-07-14 | 2007-11-01 | コロラド ステイト ユニバーシティ リサーチ ファウンデイション | パターン認識受容体−リガンド：脂質複合体を使用するワクチン |
| JP2008523819A (ja) * | 2004-12-16 | 2008-07-10 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | Ｙｅｒｓｉｎｉａｐｅｓｔｉｓの免疫療法におけるフラジェリンの使用 |
| JP2008524261A (ja) * | 2004-12-21 | 2008-07-10 | バクシネート コーポレーション | インフルエンザウイルスタンパク質の組成物およびその使用方法 |
| WO2009128950A2 (en) * | 2008-04-18 | 2009-10-22 | Vaxinnate Corporation | Deletion mutants of flagellin and methods of use |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011084967A3 (en) | 2011-11-10 |
| WO2011084967A2 (en) | 2011-07-14 |
| AU2011203740B2 (en) | 2014-11-13 |
| CN102740872A (zh) | 2012-10-17 |
| ZA201205273B (en) | 2013-09-25 |
| AU2011203740A1 (en) | 2012-07-19 |
| CA2786306A1 (en) | 2011-07-14 |
| EP2521563A2 (en) | 2012-11-14 |
| EP2521563A4 (en) | 2013-07-24 |
| MX2012007916A (es) | 2012-11-06 |
| SG182305A1 (en) | 2012-08-30 |
| KR20120129893A (ko) | 2012-11-28 |
| US20130095130A1 (en) | 2013-04-18 |
| EP2521563B1 (en) | 2016-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2858315T3 (es) | Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS | |
| Zheng et al. | Development of universal influenza vaccines based on influenza virus M and NP genes | |
| CN103957891B (zh) | 基于流感血凝素蛋白的新颖疫苗 | |
| RU2468034C2 (ru) | Иммуногенные композиции и способы | |
| EP2814837B1 (en) | Computationally optimized broadly reactive antigens for human and avian h5n1 influenza | |
| US6558673B1 (en) | Complexes of immunogens derived from RSV surface glycoprotein G covalently coupled to a support molecule | |
| Deng et al. | Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge | |
| KR102885621B1 (ko) | 미생물 감염을 치료 및 예방하기 위한 면역원성 조성물 | |
| US11806394B2 (en) | Protein-based nanoparticle vaccine for metapneumovirus | |
| KR101751376B1 (ko) | 점막 백신 | |
| JP2013516469A (ja) | 高齢者に保護免疫を提供するための方法及び組成物 | |
| JP5735121B2 (ja) | インフルエンザウィルスの組換えヘマグルチニン蛋白質及びそれを含むワクチン | |
| CN103517713A (zh) | 在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽 | |
| US20240424087A1 (en) | Multiepitope self-assembled nanoparticle vaccine platform (msn-vaccine platform) and uses there of | |
| EP3202780A1 (en) | Fusion protein comprising the n protein of a virus of the pneumovirinae subfamily | |
| HUT54732A (en) | Process for producing vaccine polypeptides | |
| EP1802746B1 (en) | Virosome particles comprising antigens from influenza virus and hepatitis b virus | |
| US20220332770A1 (en) | High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier | |
| JP2005170945A (ja) | インフルエンザ血球凝集素多価ワクチンの製造方法 | |
| RU2757013C2 (ru) | Рекомбинантная противогриппозная вакцина с широким спектром защиты и способ ее получения | |
| WO2024186901A2 (en) | Broadly reactive immunogens of influenza h3 virus, compositions and methods of use thereof | |
| WO2020034048A2 (es) | Vacuna contra el síndrome cardiopulmonar causado por hantavirus | |
| KR20250046320A (ko) | 계절성 및 신종 감염의 치료 및 예방을 위한 백신 | |
| WO2025179103A9 (en) | Pentavalent and octavalent influenza virus immunogens, compositions and methods of use thereof | |
| HK1192455A (en) | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20131226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141209 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150512 |